Factors predictive of carrying MLH1 and MSH2 germline mutations in patients with colorectal cancer (CRC) are awaited. In this population-based study, we further define the role of MLH1/MSH2 mutations through a evaluation clinic program among 362 consecutively-collected Sardinian CRC patients. Eight MLH1/MSH2 germline mutations were detected in 21 (6%) patients. Considering the family cancer history, MLH1/MSH2 mutations were found in 14/48 (29.2%) probands from CRC families and, among them, in 10/13 (76.9%) families fulfilling the Amsterdam criteria. The patients with low familial recurrence (two CRCs in family) presented a much lower frequency of MLH1/MSH2 mutations (2/55;3.6%). Significantly higher rates of MLH1/MSH2 mutations were found in patients with age of onset <45 years (P=0.012) or with >3 affected family members (P=0.009). While no significant predictive value was found for the presence of endometrial cancer within the family, earlier diagnosis age and/or familial CRC recurrence should be considered as strong predictors for the occurrence of MLH1/MSH2 mutations, useful in addressing CRC patients to genetic test.
Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma
Colombino M;Casula M;Palomba G;Pisano M;Sini MC;Palmieri G
2005
Abstract
Factors predictive of carrying MLH1 and MSH2 germline mutations in patients with colorectal cancer (CRC) are awaited. In this population-based study, we further define the role of MLH1/MSH2 mutations through a evaluation clinic program among 362 consecutively-collected Sardinian CRC patients. Eight MLH1/MSH2 germline mutations were detected in 21 (6%) patients. Considering the family cancer history, MLH1/MSH2 mutations were found in 14/48 (29.2%) probands from CRC families and, among them, in 10/13 (76.9%) families fulfilling the Amsterdam criteria. The patients with low familial recurrence (two CRCs in family) presented a much lower frequency of MLH1/MSH2 mutations (2/55;3.6%). Significantly higher rates of MLH1/MSH2 mutations were found in patients with age of onset <45 years (P=0.012) or with >3 affected family members (P=0.009). While no significant predictive value was found for the presence of endometrial cancer within the family, earlier diagnosis age and/or familial CRC recurrence should be considered as strong predictors for the occurrence of MLH1/MSH2 mutations, useful in addressing CRC patients to genetic test.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


